Ibogaine Treatment in Mexico: What You Should Know Before Considering It

Understanding Ibogaine, Treatment Programs, Medical Screening and the Importance of Choosing the Right Environment

Interest in ibogaine treatment has grown significantly in recent years, particularly among individuals and families looking for new approaches to substance dependence, opioid withdrawal, trauma and other difficult-to-treat conditions.

For Canadians and Americans researching their options, Mexico has become one of the destinations where specialized ibogaine programs are available.

But ibogaine is not a conventional treatment, and it is not something that should be approached casually.

It is a powerful psychoactive substance with potential therapeutic applications that are still being investigated. It also carries medical risks, particularly involving the heart, which makes proper screening, medical supervision and careful patient selection critically important.

At Mexico Health Concierge, our role is to help clients understand their options, organize the information they need, and coordinate initial consultations with specialized providers in Mexico.

One of the providers we are working with is an established ibogaine treatment center located in Tepoztlán, Morelos and operating since 2009. The center combines medical monitoring with psychotherapy, preparation, integration and a small-group retreat environment.

What Is Ibogaine?

Ibogaine is a psychoactive alkaloid derived from the root bark of Tabernanthe iboga, a plant native to Central and West Africa with a long history of traditional and ceremonial use.

In recent decades, researchers and treatment providers have become interested in ibogaine because of reports that it may temporarily reduce opioid withdrawal symptoms and drug cravings while producing an intense psychological experience that some individuals describe as deeply introspective.

Research has explored ibogaine primarily in relation to substance-use disorders, particularly opioid and cocaine dependence. Some observational and open-label studies have reported reductions in withdrawal symptoms, cravings and substance use following treatment.

Why Are People Considering Ibogaine for Addiction?

The area receiving the most attention is addiction interruption.

People struggling with opioids, including heroin, prescription opioids and fentanyl can face extremely difficult withdrawal symptoms and powerful cravings when attempting to stop using.

Some observational research suggests that ibogaine may temporarily reduce withdrawal severity and craving in some individuals. This potentially creates a period during which the person may be better positioned to begin longer-term psychological, behavioral and recovery work.

That is why the phrase “addiction interruption” is often used rather than “addiction cure.”

Ibogaine should not be viewed as a stand-alone solution.

Long-term recovery can still require counseling, addiction medicine, psychological support, lifestyle changes, peer support, family involvement and treatment of underlying mental-health conditions.

The period following treatment may therefore be just as important as the treatment experience itself.

What Does the Research Say About Ibogaine Outcomes?

Interest in ibogaine treatment in Mexico has grown partly because of several encouraging observational studies examining its potential effects on trauma-related symptoms, traumatic brain injury and substance dependence.

One of the most widely discussed studies was published in Nature Medicine in 2024 by researchers associated with Stanford Medicine. The prospective observational study followed 30 male U.S. Special Operations veterans with histories of predominantly mild traumatic brain injury and repeated blast exposure. The veterans had independently arranged treatment at a clinic in Mexico, where they received ibogaine together with magnesium, which was used as part of the protocol to help reduce cardiac risk.

Significant Reductions in PTSD, Depression and Anxiety

At the one-month follow-up, researchers reported substantial average reductions in psychiatric symptoms compared with baseline:

• 88% reduction in PTSD symptoms
• 87% reduction in depression symptoms
• 81% reduction in anxiety symptoms

Participants also showed a major improvement in overall functioning. Their average disability score declined from a level associated with mild-to-moderate disability before treatment to a level indicating little or no measured disability one month later. Formal cognitive testing also showed improvements in areas including concentration, information processing, memory and impulsivity.

These findings have generated considerable interest because many of the participants had been living with persistent symptoms following traumatic brain injury and combat exposure.

However, the study has important limitations. It involved only 30 participants, all of whom were male Special Operations veterans, and there was no placebo or untreated control group. The researchers themselves emphasized that controlled clinical trials are still needed to establish ibogaine’s safety and effectiveness.

What Has Research Found for Opioid Dependence?

Ibogaine has also been studied for its potential to interrupt opioid withdrawal and craving.

In a study involving 50 people with opioid-use disorder who underwent a week-long ibogaine detoxification program in Mexico, researchers found that 48 hours after ibogaine administration:

• 78% showed no objective clinical signs of opioid withdrawal
• 79% reported minimal opioid cravings
• Many participants reported substantially reduced subjective withdrawal symptoms

The authors concluded that ibogaine appeared to reduce withdrawal and craving, while stressing that more rigorous controlled research is necessary.

Another study surveying 88 people who had received ibogaine treatment in Mexico found that 80% reported that ibogaine eliminated or dramatically reduced their withdrawal symptoms. Thirty percent reported never using opioids again following treatment, while others experienced reduced use or periods of abstinence. Importantly, relapse still occurred in a substantial proportion of participants, reinforcing the idea that ibogaine should not be viewed as a stand-alone cure for addiction.

Longer-term observational research has also reported reductions in opioid withdrawal, drug-use severity and depressive symptoms following ibogaine treatment, although small sample sizes and the absence of randomized control groups make it impossible to draw definitive conclusions about effectiveness. One such study also documented a death during treatment, underscoring the importance of medical screening and safety protocols.

Promising Findings, but Not Proof of a Cure

The early research around ibogaine treatment in Mexico is encouraging, particularly in the areas of opioid withdrawal, craving, PTSD symptoms, depression, anxiety and functioning after traumatic brain injury.

At the same time, these findings should be interpreted carefully.

Ibogaine remains an investigational treatment. Most existing studies are observational, involve relatively small numbers of participants and cannot establish the same level of evidence as large randomized controlled clinical trials.

Ibogaine also carries potentially serious medical risks, particularly cardiac arrhythmias. The positive results reported in emerging research therefore do not eliminate the need for thorough medical screening, appropriate patient selection, continuous monitoring and access to qualified medical professionals.

For someone considering ibogaine, the question should not simply be “Does it work?” A more useful question is:

“What does the current evidence suggest, what are the risks, and is this treatment medically appropriate for my individual circumstances?”

Ibogaine Is Not Without Significant Risk

Anyone considering ibogaine needs to understand this part clearly.

Ibogaine can affect the electrical activity of the heart and can significantly prolong the QT interval, which is measured on an electrocardiogram or ECG/EKG.

In susceptible individuals, QT prolongation can lead to dangerous abnormal heart rhythms, including torsades de pointes and other ventricular arrhythmias. Serious adverse events temporally associated with ibogaine use have been documented.

A 2026 cardiovascular review emphasized that serious arrhythmias have occurred even at therapeutic doses and in individuals without previously recognized cardiac disease. The author stressed the importance of rigorous cardiovascular screening and monitoring.

For this reason, the medical infrastructure surrounding treatment matters enormously.

Medical Screening Before Ibogaine Treatment

One reason we believe an initial consultation and medical review should come before making travel arrangements is that not everyone is an appropriate candidate for ibogaine.

According to current treatment information, prospective clients undergo an application and medical screening process before treatment is approved.

The center currently lists required testing including:

• Blood pressure assessment
• EKG/ECG with the tracing included
• Complete blood count
• Basic metabolic panel
• Urinalysis
• Liver-function testing

Additional cardiac testing may be required for people over 60 or for individuals with certain medical conditions.

Medication history is also extremely important.

Certain medications, recreational substances, electrolyte abnormalities, heart conditions and other medical issues may increase risk. Medication changes or detoxification should never be attempted independently simply to qualify for ibogaine treatment.

Those decisions need to be made with appropriate medical professionals.

What Treatment At Our Treatment Center Looks Like

Rather than operating as a large-volume facility, the center conducts approximately one small-group treatment program each month, with a maximum of seven participants. Guests stay in private rooms in a Posada-style property with gardens and shared areas.

The current process includes several stages.

1. Application and Screening

Clients first complete an application detailing their medical history, substance-use history, medications and reasons for considering treatment. The information is reviewed before proceeding to the next stage.

2. Initial Consultation and Treatment Planning

If the initial application appears appropriate, the provider schedules a consultation to discuss medical history, treatment goals, expectations and potential contraindications. This is an important part of the process because approval should never be automatic.

3. Medical Clearance

Required laboratory work and cardiac testing must be completed before final approval. For higher-risk individuals, additional studies can be requested.

4. Preparation

Preparation sessions with psychotherapists or coaches before arrival. These sessions are designed to help clients understand the experience, establish realistic expectations and begin thinking about what they want to address during and after treatment.

5. Detoxification When Necessary

Certain individuals seeking treatment for substance dependence may require stabilization or detoxification before receiving ibogaine. Clients requiring additional detox support may arrive early and receive supervised assistance. If a more intensive detoxification program is required than the center believes it can safely provide, the client may be referred elsewhere.

6. The Treatment Week

The standard program is a seven-day, Monday-to-Monday retreat. The program can include an extended ibogaine session with medical monitoring, recovery time, therapeutic integration, individual and group therapy, meditation, breathwork, somatic work and other supportive activities.

Treatment Is Only Part of the Recovery Process

One of the most important questions to ask any ibogaine center is: What happens after treatment?

For someone struggling with addiction, stopping withdrawal or reducing cravings does not automatically resolve the circumstances that contributed to substance use.

Trauma, depression, anxiety, relationships, lifestyle, environment, coping skills and underlying psychiatric conditions may all need continuing attention.

Post-treatment integration and continued therapeutic support should be part of the overall approach.

We believe that approach is important.

Rather than viewing ibogaine as a single event that fixes everything, it may be more responsible to think of treatment, when medically appropriate, as one potential component of a much larger recovery plan.

What About Ibogaine for PTSD, Depression and Traumatic Brain Injury?

Ibogaine is also receiving attention in connection with PTSD, depression, mood disorders and traumatic brain injury.

Recent scientific reviews describe potentially interesting findings while emphasizing that larger, properly controlled clinical trials are still needed before efficacy can be established.

Anyone considering ibogaine for a psychiatric or neurological condition should therefore be particularly careful about claims of guaranteed improvement, neurological “resets” or cures.

Why Do Canadians and Americans Travel to Mexico for Ibogaine?

Regulatory status is one reason.

Health Canada states that ibogaine is not authorized for use in Canada. It was added to Canada’s Prescription Drug List in 2017 following serious and fatal adverse-reaction reports associated with its use.

In the United States, ibogaine is listed as a Schedule I controlled substance by the U.S. Drug Enforcement Administration.

As a result, some Canadians and Americans who decide to explore ibogaine treatment look internationally, including to specialized centers in Mexico.

That makes due diligence especially important.

Traveling internationally for a treatment does not reduce the medical risks of the treatment itself.

Questions to Ask an Ibogaine Treatment Center

• Who reviews the patient’s medical history and determines eligibility?

• Which cardiac and laboratory studies are required before treatment?

• Is continuous ECG and vital-sign monitoring used during ibogaine administration?

• Which physicians, nurses and emergency personnel are physically present?

• What emergency equipment and medications are available onsite?

• How are medication interactions and substance detoxification handled?

• What happens if the medical team decides the person should not receive ibogaine?

• What psychological preparation is provided?

• What integration and aftercare are included?

• What is the plan if the client needs a higher level of medical care?

A reputable intake process should sometimes result in a patient being told no.

That is not a weakness. It can be an important sign that medical suitability is being taken seriously.

The Role of Mexico Health Concierge

Mexico Health Concierge does not administer ibogaine and does not determine whether someone is medically appropriate for treatment.

Those decisions belong to the independent physicians and treatment professionals providing the care.

Our role is to help clients and families navigate the process.

For clients interested in exploring treatment, MHC can help coordinate:

• An initial consultation with the treatment center
• Collection and organization of relevant medical information
• Communication with the provider
• Required testing coordination where appropriate
• Travel planning
• Transportation arrangements
• Accommodation and logistical support
• Communication with accompanying family members
• Follow-up coordination

The first goal is not to convince someone to undergo treatment. It is to help them obtain enough information to make an informed decision.

Considering Ibogaine Treatment in Mexico?

Ibogaine is one of the more interesting and controversial areas of emerging addiction research.

There are encouraging observations, particularly around opioid withdrawal and craving. At the same time, scientific evidence remains incomplete and the cardiovascular risks are real.

Both of those things can be true at the same time.

For someone seriously considering ibogaine, the most important first step is therefore not booking a flight or reserving a treatment.

It is careful medical screening and a detailed consultation with an experienced treatment team.

Mexico Health Concierge can help coordinate that first conversation.

If you or a family member would like to explore whether an ibogaine program in Mexico may be appropriate, contact Mexico Health Concierge and we can help arrange an initial consultation with our Ibogaine Center.

Mexico Health Concierge
Personalized Healthcare in Mexico, Guided by People Who Truly Care.

Important Information

Mexico Health Concierge provides non-clinical healthcare navigation, coordination and concierge support. MHC does not administer ibogaine and is not responsible for determining medical suitability, diagnosis, treatment decisions or clinical outcomes. Ibogaine is an investigational psychoactive substance with potentially serious adverse effects, including cardiac arrhythmias. Evidence regarding its effectiveness for addiction, PTSD, depression, traumatic brain injury and other conditions remains limited and continues to evolve. Individuals should discuss treatment risks, alternatives, medications, medical history and suitability with qualified healthcare professionals before making a treatment decision.